Novartis: pediatric ophthalmic drug wins EU recommendation
(CercleFinance.com) - Novartis has received a positive opinion from European regulators recommending marketing authorisation of its treatment for preterm infants with retinopathy of prematurity, a disease causing visual impairment or even blindness.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Lucentis for this rare eye disease, the Swiss drugmaker said.
The European Commission will review the CHMP opinion and is expected to deliver its final decision in the next three months.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Lucentis for this rare eye disease, the Swiss drugmaker said.
The European Commission will review the CHMP opinion and is expected to deliver its final decision in the next three months.
Copyright (c) 2019 CercleFinance.com. All rights reserved.